### Warfarin

#### Indication
Venous thromboembolism

**ICD11 code:** BD72

#### INN
Warfarin

#### Medicine type
Chemical agent

#### List type
- Core (EML)
- Complementary (EMLc)

#### Formulations
Oral > Solid: 5 mg (sodium salt) ; 1 mg (sodium salt) ; 2 mg (sodium salt) ; 0.5 mg (sodium salt)

#### EML status history
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1982 (TRS 685)
- Changed in 1987 (TRS 770)
- Changed in 2007 (TRS 950)

#### Sex
All

#### Age
Also recommended for children

#### Therapeutic alternatives
Medicines within the same pharmacological class can be used

#### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

#### Wikipedia
[Warfarin](https://en.wikipedia.org/wiki/Warfarin)

#### DrugBank
[Warfarin](https://www.drugbank.ca/drugs/DB00008)

### Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee accepted that medicines affecting coagulation were essential for children and endorsed the inclusion of warfarin (with square box listing) on the EMLc. Because of the need for specialist supervision of the administration of warfarin in children, the Subcommittee recommended that warfarin be included in the Complementary List for Section 10.2. The Subcommittee also recommended the addition of warfarin 0.5 mg tablets to the EMLc.